{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:08:06Z","timestamp":1758892086111,"version":"3.32.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jns.2024.123046","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T13:59:19Z","timestamp":1715522359000},"page":"123046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification"],"prefix":"10.1016","volume":"461","author":[{"given":"Charalampos","family":"Skarlis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Raftopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clio P.","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Eleftheria","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jns.2024.123046_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2024.123046_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"360","key":"10.1016\/j.jns.2024.123046_bb0015","doi-asserted-by":"crossref","first-page":"577721","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis","author":"Sriwastava","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2024.123046_bb0020","doi-asserted-by":"crossref","first-page":"102842","DOI":"10.1016\/j.msard.2021.102842","article-title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: an effect of improved PML risk surveillance","volume":"50","author":"K\u00e5gstr\u00f6m","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.jns.2024.123046_bb0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2024.123046_bb0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jns.2024.123046_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000223","article-title":"Natalizumab-induced POU2AF1\/Spi-B upregulation: a possible route for PML development","volume":"3","author":"Meira","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"12","key":"10.1016\/j.jns.2024.123046_bb0040","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/jcp.24089","article-title":"Reactivation of human polyomavirus JC in patients affected by psoriasis vulgaris and psoriatic arthritis and treated with biological drugs: preliminary results","volume":"227","author":"Nardis","year":"2012","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.jns.2024.123046_bb0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol."},{"issue":"20","key":"10.1016\/j.jns.2024.123046_bb0050","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jns.2024.123046_bb0055","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123046_bb0060","doi-asserted-by":"crossref","first-page":"103995","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.jns.2024.123046_bb0065","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.jns.2024.123046_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/ejh.13751","article-title":"Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies","volume":"108","author":"Diamantopoulos","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jns.2024.123046_bb0075","doi-asserted-by":"crossref","first-page":"1016377","DOI":"10.3389\/fneur.2022.1016377","article-title":"Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies","volume":"13","author":"Hatchwell","year":"2022","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2024.123046_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/WCO.000000000000563","article-title":"B cells in multiple sclerosis","volume":"31","author":"Sospedra","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123046_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B cells in multiple sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2024.123046_bb0090","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri888","article-title":"Viruses and interferon: a fight for supremacy","volume":"2","author":"Katze","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jns.2024.123046_bb0095","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren\u2019s syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jns.2024.123046_bb0100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123046_bb0105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123046_bb0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCVTM DxSelectTM) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"3","key":"10.1016\/j.jns.2024.123046_bb0115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/acn3.51130","article-title":"Improving risk-stratification of natalizumab-associated PML","volume":"8","author":"Tugemann","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2024.123046_bb0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","article-title":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Borchardt","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123046_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.jns.2024.123046_bb0130","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"51","key":"10.1016\/j.jns.2024.123046_bb0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","article-title":"B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren\u2019s syndrome","author":"Nezos","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jns.2024.123046_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836824","article-title":"Genetic variants of the BAFF gene and risk of fatigue among patients with primary Sj\u00f6gren\u2019s syndrome","volume":"13","author":"Flessa","year":"2022","journal-title":"Front. Immunol."},{"issue":"92","key":"10.1016\/j.jns.2024.123046_bb0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaut.2018.05.002","article-title":"B-cell activating factor and related genetic variants in lupus related atherosclerosis","author":"Theodorou","year":"2018","journal-title":"J. Autoimmun."},{"issue":"15","key":"10.1016\/j.jns.2024.123046_bb0150","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","article-title":"SNPStats: a web tool for the analysis of association studies","volume":"22","author":"Sol\u00e9","year":"2006","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.jns.2024.123046_bb0155","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/cr.2009.33","article-title":"A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http:\/\/analysis.bio-x.cn)","volume":"19","author":"Li","year":"2009","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.jns.2024.123046_bb0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cr.7290272","article-title":"SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci","volume":"15","author":"Shi","year":"2005","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.jns.2024.123046_bb0165","first-page":"386","article-title":"Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies","volume":"17","author":"Tonk","year":"2017","journal-title":"Pharm. J."},{"issue":"7","key":"10.1016\/j.jns.2024.123046_bb0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.gene.6363923","article-title":"Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis","volume":"3","author":"Kawasaki","year":"2002","journal-title":"Genes Immun."},{"issue":"9","key":"10.1016\/j.jns.2024.123046_bb0175","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/rheumatology\/ken246","article-title":"Polymorphism in the 5\u2032 regulatory region of the B-lymphocyte activating factor gene is associated with the Ro\/La autoantibody response and serum BAFF levels in primary Sjogren\u2019s syndrome","volume":"47","author":"Nossent","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jns.2024.123046_bb0180","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hon.3008","article-title":"B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and non-Hodgkin\u2019s lymphoma","volume":"40","author":"Gragnani","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.jns.2024.123046_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.579438","article-title":"New algorithms improving PML risk stratification in MS patients treated with Natalizumab","volume":"11","author":"Toboso","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.123046_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.698121","article-title":"Sexual dimorphism and gender in infectious diseases","volume":"12","author":"Gay","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2024.123046_bb0195","doi-asserted-by":"crossref","first-page":"155964","DOI":"10.1016\/j.cyto.2022.155964","article-title":"Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: hypothesis generating insights from COVID-19 convalescent individuals","volume":"157","author":"Mavragani","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.jns.2024.123046_bb0200","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12881-019-0906-8","article-title":"Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility","volume":"20","author":"Deng","year":"2019","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.jns.2024.123046_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.945762","article-title":"Sex bias in lymphocytes: Implications for autoimmune diseases","volume":"13","author":"Dodd","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2024.123046_bb0210","doi-asserted-by":"crossref","first-page":"109847","DOI":"10.1016\/j.clim.2023.109847","article-title":"B-cell activating factor gene variants in multiple sclerosis: possible associations with disease susceptibility among females","volume":"257","author":"Skarlis","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jns.2024.123046_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120459","article-title":"Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review","volume":"443","author":"Sharma","year":"2022","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:30:30Z","timestamp":1736184630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":43,"alternative-id":["S0022510X24001813"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123046","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123046"}}